Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Urethra-Sparing is Contraindicated in Radical Cystoprostatectomy for TCCA of the Bladder Point/Counterpoint No: Bernard B. Bochner, M.D. (Urethra-Sparing SHOULD be done) Yes: Douglas S. Scher, M.D. (Urethra-Sparing should NOT be done) Moderator: Michael J. Droller, M.D. Definition of the Debate Define histopathologic findings to consider Describe clinical scenarios that determine impressions Identify outcomes that guide refinements of opinions Consider risks, benefits, advantages and disadvantages of each approach Conclude to agree or disagree, establish boundaries, and understand areas for further study Topics for Discussion Histopathologic aspects of transitional cell cancer of the bladder that introduce the issue of urethrectomy vs a urethra-sparing approach Clinical considerations Definition of urethra-sparing approaches and surgical considerations (including open surgery vs laparoscopy/robotics) Topics for Discussion Risks and side effects of urethrectomy vs urethrasparing surgery Advantages and disadvantages of urethrectomy vs urethra-sparing surgery Manner of follow-up and its reliability Considerations of early vs delayed urethrectomy Outcomes of cystectomy with or without urethrectomy in various histopathologic and clinical settings Schedule of Debate Bochner (8-9 minutes): Urethra-sparing should be done Scher (8-9 minutes): Urethra-sparing should not be done Bochner (2-3 minutes): Rebuttal Scher (2-3 minutes): Rebuttal Droller: Summary and Conclusions